

PRESS RELEASE



TheraVet raises 4 M€ to accelerate the development of its two veterinary products

Jumet (Wallonia, Belgium), December 10th, 2020 - TheraVet S.A., a company specialized in treatment of the osteoarticular diseases in small companion animals, **announced today that it will raise by the end of 2020 €4 million of additional funding for the development of its innovative veterinary product lines.**

This funding consists of a capital increase of €1.9 million realized with TheraVet's historical shareholders which include: the fund Theodorus III, the fund Innovation Fund, the regional investment funds Financière Spin-Off Luxembourgeoise and the Luxembourg Développement Europe 2 and Business Angels. It is completed by non-dilutive financing¹ granted by the Walloon Region for €2.1 million. With this financing, since its creation in November 2017, TheraVet will have raised a total of €7.3 million.

The raised funds will be used for the development and advancement of TheraVet's two innovative veterinary product lines: **BIOCERA-VET**, which is expected to be commercially launched for the applications of bone surgery in the second quarter of 2021 and **VISCO-VET**, currently being prepared for evaluation in a confirmatory clinical study in canine osteoarthritis in Europe.

Enrico Bastianelli, CEO of TheraVet, said: *"We are very happy to receive this funding, which once again demonstrates the confidence placed in us by our investors and the Walloon Region. Over the past two years, TheraVet has reached significant milestones in the development of BIOCERA-VET and VISCO-VET, its two innovative veterinary products to improve the management and treatment of osteoarticular diseases in pets. This financing will contribute to*

¹ Obtained in the form of grants, loans and recoverable advances to specifically support research and development programs.

TheraVet's transition from the clinical stage to the market by providing us with the necessary funds for the commercial launch of our first line of therapeutic products.”



About BIOCERA-VET

BIOCERA-VET is a line of injectable synthetic self-hardening calcium-phosphate bone substitutes. BIOCERA-VET, a new veterinary medical device, presents unique properties combining ideal bone formation and remodelling properties associated to mechanical resistance. BIOCERA-VET targets bone surgeries (such as arthrodesis, fractures) and osteosarcoma in small companions (dogs and cats) and bone cyst in horses.

About VISCO-VET

VISCO-VET is a hyaluronan-based visco-regenerative gel supplemented with an anti-inflammatory agent. VISCO-VET is a freeze-dried product developed for local and minimally invasive treatment of osteoarticular disorders in dogs. Thanks to its unique composition, VISCO-VET is an injectable solution with gelification properties allowing a prolonged effect of active agent in the affected joint. VISCO-VET targets osteoarticular diseases as osteoarthritis and cranial cruciate ligament deficiency in dogs.

About TheraVet

TheraVet is a vet company created in November 2017 by Enrico Bastianelli, MD, MBA, and based in Jumet, Belgium. The Company specializes in the treatment of osteoarticular diseases in small companion animals, such as dogs, using a portfolio of biological and synthetic products. TheraVet currently has two product lines: BIOCERA-VET, a line of injectable synthetic self-hardening high porosity calcium-phosphate bone substitutes and VISCO-VET, a versatile line of injectable hyaluronan-based visco-regenerative gel with anti-inflammatory and pro-regenerative properties.

Media Contacts

NewCap

France

Arthur Rouillé

arouille@newcap.fr

+33 (0)1 44 71 00 15

TheraVet S.A.

11b, rue d'Edimbourg
6040 Jumet
Belgium

TheraVet USA

1716 Briarcrest Dr. Suite 714
Bryan, Texas, 77802
USA

Connect with us via info@thera.vet, TheraVet [LinkedIn](#) or www.thera.vet

